Scapulatempo-Neto C et al.Characterization of topoisomerase II a and minichromosome maintenance protein 2 expression in anal carcinoma.Oncol Lett 13:1891-1898 (2017).
Guturi KK et al.RNF168 and USP10 regulate topoisomerase IIa function via opposing effects on its ubiquitylation.Nat Commun 7:12638 (2016).
Lopez-Mosqueda J et al.SPRTN is a mammalian DNA-binding metalloprotease that resolves DNA-protein crosslinks.Elife 5:N/A (2016).
d'Alcontres MS et al.TopoIIa prevents telomere fragility and formation of ultra thin DNA bridges during mitosis through TRF1-dependent binding to telomeres.Cell Cycle 13:1463-81 (2014).
Kim MK et al.Loss of compensatory pro-survival and anti-apoptotic modulator, IKKe, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21.Oncotarget 5:12788-802 (2014).
Dykhuizen EC et al.BAF complexes facilitate decatenation of DNA by topoisomerase IIa.Nature 497:624-7 (2013).
Taniai E et al.Ochratoxin A induces karyomegaly and cell cycle aberrations in renal tubular cells without relation to induction of oxidative stress responses in rats.Toxicol Lett 224:64-72 (2013).
Kimura M et al.Involvement of multiple cell cycle aberrations in early preneoplastic liver cell lesions by tumor promotion with thioacetamide in a two-stage rat hepatocarcinogenesis model.Exp Toxicol Pathol 65:979-88 (2013).
Gardner L et al.Geminin overexpression prevents the completion of topoisomerase IIa chromosome decatenation, leading to aneuploidy in human mammary epithelial cells.Breast Cancer Res 13:R53 (2011).
Park JS et al.Topoisomerase II alpha as a universal tumor antigen: antitumor immunity in murine tumor models and H-2K(b)-restricted T cell epitope.Cancer Immunol Immunother 59:747-57 (2010).
Adler M et al.Modulation of key regulators of mitosis linked to chromosomal instability is an early event in ochratoxin A carcinogenicity.Carcinogenesis 30:711-9 (2009).